Table 3.
Baseline Characteristics of the Clinical Outcomes Study
| Full Cohort (n=464) | Individuals Without Subsequent CVD (n=430) | Individuals With Subsequent CVD (n=34) | p-value | |
|---|---|---|---|---|
| Age | 55 [44–46] | 54 [44–65] | 66 [60–78] | <0.001 |
| Male gender | 201 (43) | 186 (43) | 15 (44) | 0.53 |
| Current smoker | 46 (10) | 36 (8.5) | 10 (29) | 0.001 |
| Hypertension | 158 (34) | 139 (32) | 19 (56) | 0.006 |
| Diabetes Mellitus | 41 (9) | 34 (8) | 7 (20) | 0.02 |
| Statin use | 89 (19) | 75 (17) | 14 (41) | 0.002 |
| BMI (kg/m2) | 26 [23–31] | 26 [23–31] | 27 [24–32] | 0.33 |
| Dyslipidemia | 127 (27) | 112 (26) | 15 (44) | 0.02 |
| Baseline values | ||||
| Total cholesterol, mg/dl | 192±45 | 193±45 | 184±41 | 0.32 |
| LDL cholesterol, mg/dl | 111±38 | 112±32 | 107±34 | 0.49 |
| HDL cholesterol, mg/dl | 56±18 | 57±19 | 50±14 | 0.04 |
| Triglycerides, mg/dl | 124±72 | 121±72 | 140±71 | 0.18 |
| FRS* | ||||
| <10 | 186 (82) | 168 (85) | 18 (60) | 0.08 |
| 10–20 | 36 (16) | 24 (12) | 12 (40) | <0.001 |
| >20 | 5 (2) | 5 (2.5) | 0 (0) | 0.68 |
| FDG Uptake† | ||||
| Bone Marrow | 2.2 [1.9–2.6] | 2.2 [1.9–2.6] | 2.4 [2.1–2.8] | 0.03 |
| Spleen | 2.1 [1.8–2.4] | 2.1 [1.8–2.3] | 2.2 [2.1–2.5] | 0.01 |
| Arterial wall | 1.9 [1.8–2.2] | 1.9 [1.8–2.2] | 2.2 [1.9–2.3] | <0.001 |
| Subcutaneous Adipose Tissue (SAT) | 0.17 [0.14–0.2] | 0.16 [0.14–0.2] | 0.19 [0.13–0.22] | 0.28 |
Values are presented as mean ± standard deviation, median [IQR] or n (%).
*
A subset of 227 subjects provided all the required data to calculate FRS.
†
FDG uptake in bone marrow, spleen and SAT is reported as SUV whereas arterial FDG uptake is reported as TBR.
Abbreviations: BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein